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Abstract
 
The chemokine receptor CCR5 plays an important role in leukocyte chemotaxis and activa-
tion, and also acts as a coreceptor for human and simian immunodeficiency viruses (HIV-1,
HIV-2, and SIV). We provide evidence that CCR5 is O-glycosylated on serine 6 in the NH
 
2
 
terminus. The O-linked glycans, particularly sialic acid moieties, significantly contribute to
binding of the chemokine ligands. By contrast, removal of O-linked oligosaccharide exerted
little effect on HIV-1 infection. Sulfation of specific tyrosine residues in the CCR5 NH
 
2
 
 ter-
minus was important for efficient 
 
 
 
-chemokine binding. Thus, as has been observed for the
binding of selectins and their ligands, O-linked carbohydrates and tyrosine sulfates play major
roles in promoting the interaction of chemokines with CCR5. The resulting flexible arrays of
negative charges on the CCR5 surface may allow specific, high-affinity interactions with di-
verse chemokine ligands. Although this is the first example of O-linked oligosaccharides and
tyrosine sulfates playing a role in chemokine binding, the high density of serines, threonines
and tyrosines in the N-termini of many CC chemokine receptors suggests that these posttrans-
lational modifications may commonly contribute to chemokine binding.
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Introduction
 
Chemokines are a large family of cytokines mainly in-
volved in cell traffic coordination and cell activation during
immunological processes (1, 2). All chemokines act via a
subclass of G protein–coupled, seven-transmembrane-seg-
ment receptors (GPCRs)
 
*
 
 (3). CC chemokine receptor
(CCR)5, a functional receptor with high affinity for mac-
rophage inflammatory protein (MIP)-1
 
 
 
, MIP-1
 
 
 
, regu-
lated on activation normal T cell expressed (RANTES),
and some other 
 
 
 
-chemokines has been found on several
cell types including memory T cells, B cells, macrophages,
microglia, mast cell precursors, and dendritic cells (1–4).
Together with CD4, CCR5 serves as a coreceptor facilitat-
ing the entry of HIV-1, HIV-2, and simian immunodefi-
ciency virus (SIV) into target cells (5, 6). Primary infection
with these viruses is predominantly mediated by so-called
R5 viral strains that utilize CCR5. Later in the course of
HIV-1 infection, X4 viral strains often emerge that utilize
another chemokine receptor, CXC chemokine receptor
(CXCR)4. The emergence of X4 or dual tropic R5X4 vi-
ral subtypes is typically associated with rapid deterioration
of the immune system and development of AIDS (7).
Approximately 1% of Caucasians are homozygous for a
32-base pair deletion in the CCR5 gene. These individu-
als produce a nonfunctional protein and thus are highly re-
sistant to HIV-1 infection, demonstrating the pivotal role
of CCR5 for viral transmission (8). Individuals lacking
CCR5 are immunologically competent, a phenotype that
may reflect the high degree of redundancy in the chemo-
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kine system. The ability of healthy individuals to withstand
the absence of CCR5 has stimulated efforts to develop
specific CCR5 inhibitors for antiretroviral therapy (9).
Natural chemokine ligands, monoclonal antibodies, and
small nonpeptide compounds like TAK-779 can inhibit
HIV-1 entry in vitro (10, 11) and are being considered for
in vivo applications.
Precise knowledge of the structural basis for chemokine
and HIV-1 envelope glycoprotein binding to CCR5
would advance our understanding of the role of CCR5 in
physiology and disease, and inform efforts to develop po-
tent drugs for therapeutic intervention. Like other GPCRs,
CCR5 has an amino terminus and three extracellular loops.
The NH
 
2
 
 terminus and the second extracellular loop of
CCR5 contribute to high affinity binding of chemokines
and the HIV-1 gp120 exterior envelope glycoprotein, but
other CCR5 domains can also influence these associations
(12–14). A current model for chemokine binding suggests a
two-step mechanism involving an initial association with
the probably more exposed CCR5 NH
 
2
 
 terminus and a
subsequent, more specific, interaction with the CCR5 ex-
tracellular loops leading to receptor activation (12, 15, 16).
Deletion of the NH
 
2
 
-terminal sequences of CCR5 strongly
impairs chemokine binding, but substitution of this domain
with corresponding regions from related receptors, includ-
ing CCR1, CCR2b, CXCR2, and CXCR4, can restore
chemokine binding and receptor activation (12, 13, 17).
Therefore, similar determinants in the NH
 
2
 
 terminus
shared among related receptors likely contribute to high af-
finity binding of chemokines (13). Negatively charged and
aromatic residues in the NH
 
2
 
-terminal region of CCR5 are
crucial for the association with chemokines and the HIV-1
gp120 envelope glycoprotein (13, 14, 17–20). Sulfate moi-
eties on tyrosines contribute extra negative charges to this
region and facilitate HIV-1 entry (21). Inhibition of tyro-
sine sulfation substantially decreases the affinity of MIP-1
 
 
 
,
MIP-1
 
 
 
, and HIV-1 gp120/CD4 complexes for CCR5
(21).
In addition to tyrosine sulfation, CCR5 is also modified
by O-linked oligosaccharides (O-glycans), which are typi-
cally added to serine or threonine residues in the Golgi
compartment of the cell (21). In the cell types examined to
date, the O-glycans on CCR5 are not sulfated themselves
but contain negatively charged terminal sialic acid residues
(21). The functions of O-glycans are as diverse as their
structure. These include the maintenance of protein con-
formation, protection of proteins from proteases, control of
active epitopes and antigenicity, blood clotting, embryo-
genesis, development, participation in cell-egg binding,
and microbe attachment to cells (22, 23). Of special interest
is the contribution of sialylated O-glycans to the adhesion
of activated immune cells and to the metastatic potential of
cancer cells (24).
In this paper, we report the location of the major O-gly-
cosylation site of CCR5 expressed in several cell lines as
well as in primary macrophages. We analyze the contribu-
tion of CCR5 O-glycosylation to chemokine binding and
HIV-1 entry. Finally, we extend our studies on tyrosine
 
sulfation in the CCR5 NH
 
2
 
 terminus and investigate its
role in chemokine binding.
 
Materials and Methods
 
Cells.
 
Cf2Th cells (canine thymocytes), HeLa, and HEK
293T cells were obtained from the American Type Culture Col-
lection. Cells were maintained in Dulbecco’s modified Eagle’s
medium containing 10% fetal calf serum, 100 U of penicillin/ml,
and 100 U of streptomycin/ml. LdlD and Chinese hamster ovary
(CHO) cells were kindly provided by Dr. M. Krieger (Massachu-
setts Institute of Technology, Cambridge, MA) and maintained
in F12 medium supplemented with 10% FCS and antibiotics. 3 d
before an experiment, ldlD cells were split into two flasks and
cultured in F12 medium containing antibiotics, 1
 
 
 
 ITS-supple-
ment, and 2% dialyzed FCS. The following day the medium in
one flask was supplemented with 500 
 
 
 
M N-acetylgalactosamine
(GalNAc) and 50 
 
 
 
M galactose (Gal).
Monocyte-derived rhesus macrophages were obtained and
cultured as described previously (25). Approximately 5 
 
 
 
 10
 
6
 
mononuclear cells, isolated on a Ficoll-Paque gradient, were
seeded in each well of a 6-well plate and cultured in macrophage-
driving medium (25) containing 50 U GM-CSF and 5 U
M-CSF. Nonadherent cells were removed every second day by
extensive washes with PBS.
 
Plasmids.
 
A previously described pcDNA3.1-based expres-
sion plasmid (26) for human codon-optimized CCR5 with a
COOH-terminal C9 tag (TETSQVAPA) was used as a template
to generate CCR5 mutants. The mutations specifying changes in
the CCR5 NH
 
2
 
 terminus were introduced by PCR amplification
using Pfu-polymerase and 5
 
 
 
-primers with changes of serine/
threonine codons into alanine codons, along with appropriate re-
striction sites for cloning. The 5
 
 
 
 primers were as follows, with
the mutated nucleotides underlined: AATS mutant: GAATT-
CAAGCTTGCCGCCGCCATGGACTACCAGGTG
 
GCGG
 
-
 
CG
 
CCCATCTACGACATCAACTACTAC; SSAA mutant:
GAATTCAAGCTTGCCGCCGCCATGGACTACCAGGT-
GTCCTCCCCATCTACGACATCAACTACTAC
 
GCGGCG
 
-
 
G
 
AGCCCTGCCAGAAGATC; AAAA mutant: GAATTCA-
AGCTTGCCGCCGCCATGGACTACCAGGTG
 
GCGGCG
 
-
CCCATCTACGACATCAACTACTAC
 
GCGGCG
 
GAGCC-
CTGCCAGAAGATC; ASTS mutant: GAATTCAAGCTT-
GCCGCCGCCATGGACTACCAGGTG
 
GCG
 
TCCCCCAT-
CTACGACATCAACTACTAC; SATS mutant: GAATTC-
AAGCTTGCCGCCGCCATGGACTACCAGGTGTCC
 
GC
 
-
 
G
 
CCCATCTACGACATCAACTACTAC.
The 3
 
 
 
 primer for all of the above mutants anneals to the
region encoding the C9 tag of the CCR5 gene and has the fol-
lowing sequence: CCTCTAGACTCGAGCGGCCGCTTAG-
GCGGGGGC. The mutated CCR5 genes were amplified by
PCR and ligated into the pcDNA 3.1 vector using the HindIII
and NotI restriction sites. Analogous amplified fragments were
also cloned into the pSIvec1
 
 
 
env plasmid (25) using AgeI and
NotI restriction sites and sequenced to confirm the alterations.
The plasmids pSIvec1
 
 
 
envhuCCR5, pHCM-vesicular stomatitis
virus G protein
 
 (
 
VSV-G), and psrev used to generate VSV
G-pseudotyped viruses encoding huCCR5 are described in (25)
and references therein.
The QuikChange Mutagenesis kit (Stratagene) was used to
generate the CCR5 mutants with serine/threonine residues in
the second and third extracellular loops changed to alanine. The
primers were as follows (only one primer for each mutant is 
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shown, as the second primer was simply the reverse comple-
ment): second extracellular loop mutant: CAGAAGGAGGGC-
CTGCACTAC
 
GCG
 
TGC
 
GCCGCC
 
CACTTCCCCTACTC-
CCAG; third extracellular loop mutant: CAGGAGTTCT-
TCGGCCTGAACAATTGC
 
GCCGCCGCC
 
ACCGCCTGG-
ACCAGGC. MluI and MfeI restriction sites were engineered
into the respective primers to allow for identification of positive
clones, which were subsequently sequenced. The mutant
CCR5
 
 
 
2–17 was generated in a similar way, using a 5
 
 
 
-primer
encoding a deletion of the sequence coding for amino acids 2–17.
Cf2Th cells stably expressing human CCR5 variants were es-
tablished by transfection using the calcium phosphate method and
G418 selection. Cells expressing high and comparable surface lev-
els of wild-type and CCR5 mutants, based on staining with dia-
lyzed phycoerythrin-conjugated 2D7 antibody (BD PharMin-
gen), were selected by sorting on a MoFlo FACS
 
®
 
 (Cytomatics)
machine and cultured in the presence of G418. To maintain con-
sistent expression levels, it was necessary to resort the stable cell
lines intermittently. LdlD cells stably expressing human CCR5
were established using the same approach.
Transient expression of CCR5 variants was achieved by trans-
fecting Cf2Th, Cf2Th-CD4, HEK 293T, HeLa, and CHO cells
with 25 
 
 
 
g of each expression vector using the calcium phos-
phate method. Two days after transfection, the surface expression
level of CCR5 was determined using phycoerythrin-conjugated
2D7 or 3A9 antibodies (BD PharMingen). Transfectants showing
less than 25% variation in expression of the different CCR5 vari-
ants were used for immunoprecipitation, chemokine binding, or
virus entry experiments.
To express human CCR5 and glycosylation mutants in
primary rhesus macrophages, recombinant VSV G-pseudotyped
viruses were produced in HEK 293T cells. Recombinant
viruses  were generated using the SHIV-derived vector
pSIvec1
 
 
 
envhuCCR5 or analogous vectors (25) with changes of
serines/threonines in the CCR5 sequence, as described above.
Macrophages were transduced overnight with 30,000 reverse
transcriptase (RT) units of virus. 48 h later, the macrophages
were lysed and the CCR5 protein was immunoprecipitated.
 
Labeling, Immunoprecipitation, and Glycosidase Treatment of
CCR5 Variants.
 
To label and immunoprecipitate the CCR5
proteins, all cells but macrophages were grown to confluency in
10-cm dishes. Primary macrophages were cultured in 6-well
plates and 2–3 wells were used for each CCR5 variant. Cells
were washed with PBS and labeled overnight with [
 
35
 
S]cysteine/
methionine in cysteine- and methionine-free medium or with
[
 
3
 
H]galactose in glucose-free medium. Cells were then washed
with PBS and lysed using 1 ml lysis buffer consisting of 100 mM
(NH
 
4
 
)
 
2
 
SO
 
4
 
, 20 mM Tris-HCl (pH 7.5), 10% glycerol, 1% Cy-
mal-5 (Anatrace), 0.1% SDS, and one tablet of Complete™ Pro-
tease Inhibitor Mixture (Roche) per 50 ml. Labeled receptor was
immunoprecipitated using the C9 tag-specific 1D4 antibody (Na-
tional Cell Culture Center) covalently linked to Sepharose beads
(Amersham Pharmacia Biotech). Precipitates were washed five
times in lysis buffer, incubated at 56
 
 
 
C for 20 min in reducing
sample buffer, analyzed by 10% SDS-PAGE, and visualized by
autoradiography.
For removal of O-glycan chains, Sepharose beads containing
the immunoprecipitated CCR5 proteins were washed twice with
PBS to remove detergent, divided, and one half was treated over-
night at 37
 
 
 
C with an O-glycosidase mix (
 
 
 
2–3,6,8,9-neuramini-
dase, 
 
 
 
1,4-galactosidase, endo-
 
 
 
-N-acetylgalactosaminidase, and
 
 
 
-N-acetylglucosaminidase present in the Glycoprotein Degly-
cosylation Kit from Calbiochem.
 
To remove sialidase moieties from CCR5 present on the cell
surface, 2 
 
 
 
 10
 
7
 
 cells were detached with 5 mM EDTA in PBS,
washed once with medium, and 50% of the cells were treated for
1.5 h at 37
 
 
 
C with 0.3 U of sialidase from 
 
Arthrobacter ureafaciens
 
(Roche) in 200 
 
 
 
l medium without FCS and 0.1% sodium azide.
The other 50% were incubated in the same medium under the
same conditions, but without enzyme. Cells were then used for
immunoprecipitation or for chemokine binding assays.
 
Chemokine Binding Assay.
 
Cells were detached from the
flasks with 5 mM EDTA in PBS, washed with medium without
FCS, counted, and resuspended in binding buffer (50 mM
HEPES, pH 7.5, 150 mM NaCl, 1 mM CaCl
 
2
 
, 5 mM MgCl
 
2
 
,
and 5% dialyzed FCS). Competition binding assays were per-
formed for 1 h at 37
 
 
 
C with 5 
 
 
 
 10
 
5
 
 cells, 0.1 nM 
 
125
 
I-labeled
chemokine (Dupont NEN) and varying concentrations of cold
chemokine (100 pM-1 
 
 
 
M) in 100 
 
 
 
l volumes. Cells with
bound chemokines were washed twice with binding buffer and
counted in a gamma counter. In parallel with the binding experi-
ment, the expression level of each CCR5 variant was analyzed
with phycoerythrin-conjugated 2D7 and/or 3A9 antibody on a
FACScan™ cytometer (Becton Dickinson) with CELLQuest™
software. Binding data were analyzed using GraphPad Prism soft-
ware running an algorithm for nonlinear regression of homolo-
gous one-site competition binding with ligand depletion (27) to
obtain relative K
 
d
 
 values.
 
Calcium Mobilization by CCR5 Variants.
 
Chemokine-induced
Ca
 
2
 
 
 
 influx in Cf2Th cells stably expressing different CCR5 vari-
ants was measured after transfecting these cells with a plasmid en-
coding the G protein component G
 
 
 
16
 
. Preliminary experiments
showed that G
 
 
 
16
 
 expression strongly enhanced ligand-triggered
Ca
 
2
 
 
 
 influx into CCR5-expressing Cf2Th cells. Cells were loaded
with the indicator dye Fura 2/AM (Molecular Probes) for 1 h at
37
 
 
 
C in 20 mM Hepes, pH 7.4, 125 mM NaCl, 1 mM CaCl
 
2
 
, 1
mM MgCl
 
2
 
, 5 mM KCl, 0.5 mM glucose, and 0.2% BSA. Cells
were then washed twice in the same buffer without dye and resus-
pended in new buffer at a density of 2 
 
 
 
 10
 
6
 
/ml. Changes in in-
tracellular Ca
 
2
 
 
 
 concentration in response to chemokine binding
were measured by monitoring the emission at 510 nm of the exci-
tations at 340 and 380 nm as a function of time.
 
Virus Entry Assay.
 
The efficiency of HIV-1 entry into cells
was determined using pseudotyped single-round viruses encoding
a chloramphenicol acetyltransferase (CAT) reporter gene in a
previously published env complementation assay (6). The recom-
binant HIV-1 were generated in HeLa cells by using the
pHXBH10
 
 
 
envCAT vector and plasmids encoding HIV-1 or
SIVmac envelope glycoproteins as previously described (6, 25).
Cf2Th cells stably expressing human CD4 were transiently trans-
fected with plasmids encoding the CCR5 variants to be tested.
Cells expressing similar CCR5 levels, as determined by staining a
cell sample with the 2D7 antibody at 48 h after transfection, were
seeded in 6-well plates and infected with 5,000 RT units of a sin-
gle-round virus for 1 h. 3 d after infection, CAT activity was
measured to assess the efficiency of virus entry.
 
Results
 
Identification of Major O-linked Glycosylation Sites on
CCR5.
 
A common posttranslational modification of
GPCRs is the addition of carbohydrate chains (28). It has
been recently shown that human CCR5 is not N-glycosy-
lated, but is modified by O-glycosylation (21). To localize 
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major O-glycosylation sites, we established Cf2Th cells
stably expressing wild-type CCR5 and CCR5 mutants, all
of which contain a COOH-terminal 9-amino acid tag de-
rived from bovine rhodopsin. Cells were radiolabeled with
[
 
35
 
S]cysteine/methionine or [
 
3
 
H]galactose, lysed, and
CCR5 was immunoprecipitated with the tag-specific 1D4
antibody and analyzed by SDS-PAGE. While sequence or
structural motifs for O-glycosylation have yet to be fully
characterized, it has been observed that this modification
often occurs within surface-exposed clusters of serine or
threonine residues. Four serine/threonine clusters, two
within the NH
 
2
 
 terminus, one within the second extracel-
lular loop (residues 177, 179, 180), and one within the
third extracellular loop (residues 270–272) were identified
(Fig. 1 A). The CCR5 NH
 
2
 
 terminus contains serines at
positions 6 and 7 (cluster 1) as well as threonine 16 and
serine 17 (cluster 2) (Fig. 1 A). Deletion of amino acids
2–17 resulted in a protein (CCR5
 
 
 
2–17) that was effi-
ciently expressed on the cell surface, as documented by
staining with the 2D7 anti-CCR5 antibody (data not
shown). The CCR5
 
 
 
2–17 protein migrated with an ap-
parent molecular mass that is 4–5 kD less than the 43 kD
mass of the wild-type CCR5 (Fig. 1 B). The CCR5
 
 
 
2–17
mutant did not incorporate galactose, a sugar found in
most O-glycosylated mammalian membrane proteins. This
implies that in Cf2Th cells the extracellular loops of
CCR5 are not modified by galactose-containing carbohy-
drate chains. This interpretation was supported by our
analysis of CCR5 mutants with alterations of clusters of
serines/threonines in the second and third extracellular
loops (residues 177/179/180 and 270–272, respectively;
Fig. 1 A). When these residues were altered to alanines, no
change in the migration of the CCR5 protein on SDS-
polyacrylamide gels was observed (data not shown). We
conclude that efficient O-linked glycosylation of CCR5 is
dependent upon NH
 
2
 
-terminal sequences.
To determine which of the putative O-glycosylation
sites in the NH
 
2
 
-terminal domain of CCR5 is used, we
generated mutants in which the serine/threonine residues
at positions 6, 7, 16, and 17 were changed to alanines. In
one mutant, designated AATS to denote the identity of the
amino acids at positions 6, 7, 16, and 17, serines 6 and 7
Figure 1. Identification of the ma-
jor site of CCR5 O-glycosylation in
Cf2Th cells. (A) Primary sequence of
the CCR5 extracellular domains that
contain potential O-linked glycosyla-
tion sites (indicated by boxes). (B)
Cf2Th cells expressing wild-type
CCR5 or the CCR5 2–17 mutant,
which lacks residues 2–17, were la-
beled with [35S]cysteine/methionine
or [3H]galactose, as indicated. Cell ly-
sates were precipitated with the 1D4
antibody that recognizes a COOH-
terminal epitope tag. Precipitates were
analyzed by SDS-PAGE. (C) Cf2Th
cells stably expressing CCR5 variants
were labeled overnight with [35S]cys-
teine/methionine, lysed and incubated
with the 1D4 antibody. Precipitates were divided into equal parts, which were treated overnight with a glycosidase mixture to remove O-linked carbo-
hydrate chains or with enzyme buffer alone. The CCR5 variants are named according to the residues at positions 6, 7, 16, and 17, with SSTS being the
wild-type CCR5. (D) Cf2Th cells stably expressing CCR5 variants were labeled with [35S]cysteine/methionine, lysed and incubated with the 1D4 anti-
body. Precipitates were analyzed by SDS-PAGE. (E) [3H]galactose-labeled Cf2Th cells expressing similar surface levels of wild-type CCR5 (SSTS) and
the indicated mutants were used for immunoprecipitation with the 1D4 antibody. Precipitates were analyzed by SDS-PAGE. The experiments were per-
formed at least three times with similar results.1665 Bannert et al.
were converted to alanines. A second mutant (SSAA), with
threonine 16 and serine 17 altered to alanines, was created.
A third mutant (AAAA) had all of the serines and threo-
nines in the CCR5 NH2 terminus changed to alanines.
Cf2Th cells expressing similar surface levels of these mu-
tants, as judged by staining with the 2D7 antibody directed
against the second extracellular loop of CCR5, were estab-
lished. The cells were labeled with [35S]cysteine/methio-
nine and lysed. The wild-type and mutant CCR5 proteins
were precipitated with the 1D4 antibody, which recognizes
the C9 peptide tag at the COOH terminus of the CCR5
variants. Half of the precipitated proteins were treated with
a mixture of sialidase and O-glycosidases before analysis by
SDS-PAGE. Fig. 1 C shows that the 43-kD mature form
of the wild-type CCR5 was evident, as well as smaller
amounts of the 40-kD CCR5 precursor and multimeric
forms. Glycosidase treatment resulted in an increased mo-
bility corresponding to an  2-kD decrease in molecular
mass. The identical result was observed for the SSAA mu-
tant, indicating that threonine 16 and serine 17 are not re-
quired for O-glycosylation of CCR5 in Cf2Th cells. The
AATS and AAAA mutants migrated with an apparent mo-
lecular mass that was  2 kD less than that of wild-type
CCR5. Compared with the wild-type protein, an increase
in the amount of the CCR5 precursor was observed for
these mutants. The migration of the AATS and AAAA
mutants was not affected by glycosidase treatment. Similar
results were obtained by labeling the cells with [35S]sulfate
(data not shown), indicating that the introduced amino acid
changes and consequent effects on O-glycosylation do not
prevent tyrosine sulfation of CCR5. The results suggest
that a major O-glycosylation site on human CCR5 ex-
pressed in Cf2Th cells involves serines 6 and 7.
To characterize the site of CCR5 O-glycosylation fur-
ther, we created the ASTS and SATS mutants, which have
single serine residues at positions 6 and 7, respectively, con-
verted to alanines. Cf2Th cells expressing comparable sur-
face levels of CCR5 variants were labeled either with
[35S]cysteine/methionine or [3H]galactose, lysed and used
for precipitation by the 1D4 antibody directed against the
C9 peptide tag. Comparison of Figs. 1 D ([35S]cysteine/
methionine labeling) and 1 E ([3H]galactose labeling) indi-
cates that the ASTS and SATS mutants resembled the wild-
type CCR5 both in mobility characteristics and in the in-
tensity of labeling with [3H]galactose. These results suggest
that either serine 6 or 7 can be modified by O-linked gly-
cans, and that only one of these two potential sites is exten-
sively modified on the wild-type CCR5 protein.
As expected, the AAAA mutant did not incorporate
[3H]galactose (Fig. 1 E), consistent with the results ob-
tained with the CCR5 2–17 mutant suggesting that all of
the galactose-containing glycans on CCR5 are located in
the NH2 terminus of the protein. Of interest, the AATS
mutant did incorporate [3H]galactose, but much less effi-
ciently than wild-type CCR5. The lack of [3H]galactose la-
beling of the AAAA mutant indicates that galactose addi-
tion to the AATS mutant is dependent upon threonine 16
and/or serine 17. The lower level of galactose incorpora-
tion and the absence of detectable migration differences af-
ter glycosidase treatment of the AATS mutant suggest that
glycosylation at threonine 16 and/or serine 17 is much less
efficient or involves a smaller O-glycan with fewer galac-
tose moieties, compared with O-glycosylation of serines 6
and 7.
O-glycosylation of CCR5 in Different Cells. The O-gly-
cosylation pattern of a protein may vary, depending on the
expressing cell type (24). To examine the O-glycosylation
pattern in other cell types and compare it with the results
obtained in Cf2Th cells, we transiently expressed wild-type
CCR5 as well as the AATS and SSAA mutants in the hu-
man embryonic kidney line 293T (HEK 293T), in HeLa
cells (a human cervical carcinoma line), and in primary
rhesus monkey macrophages. The expressed proteins were
precipitated from lysates of [35S]cysteine/methionine-
labeled cells and analyzed by SDS-PAGE. Similar to the re-
sults seen in Cf2Th cells, the AATS variant migrated, in all
cells tested, with an apparent molecular mass  2 kD less
than that of the wild-type protein (Fig. 2). We conclude
that in all the cell types examined, the CCR5 serines at po-
sitions 6 and 7 are major sites of O-glycosylation.
Contribution of O-glycosylation of CCR5 to HIV-1 and SIV
Entry. The NH2 terminus of CCR5 plays an important
role in HIV-1 and SIV entry. We therefore examined the
Figure 2. Characterization of O-glycosylation of CCR5 expressed in
HEK 293T, HeLa, and primary macrophages. Wild-type (wt) and mutant
CCR5 proteins were expressed transiently in HEK 293T cells (A) and
HeLa cells (B). To express CCR5 variants in primary rhesus monkey
macrophages (C), cells were cultured for 7 d and then transduced with
30,000 RT units of VSV G-pseudotyped SHIV vectors containing the
CCR5 genes in place of the nef gene. All cells were labeled with [35S]cys-
teine/methionine overnight, lysed, and used for precipitation by the 1D4
antibody. Precipitated proteins were analyzed by SDS-PAGE.1666 CCR5 O-Glycans and Chemokine Binding
ability of HIV-1 and SIVmac strains to use CCR5 mutants
deficient in O-glycosylation for entry into Cf2Th cells sta-
bly expressing human CD4. The experiments were per-
formed with recombinant HIV-1 expressing CAT and
pseudotyped with HIV-1 or SIV envelope glycoproteins.
As shown in Fig. 3, the entry of all HIV and SIV pseudo-
types into cells expressing similar levels of AASS, SSAA, and
AAAA variants was consistently  15–25% reduced com-
pared with that of wild-type CCR5. Because virus entry
associated with even the glycosylated SSAA mutant was af-
fected, this marginal reduction is not necessarily caused by a
lack of O-glycosylation and might represent a result of the
amino acid alterations per se.
Effects of Changes in CCR5 O-glycosylation Site(s) on Che-
mokine Binding. Previous studies indicated that nega-
tively charged amino acids and sulfated tyrosines in the
CCR5 NH2 terminus are important for chemokine bind-
ing (13, 21). To investigate the impact of preventing
O-glycosylation on chemokine binding, we performed
homologous competitive binding studies using the CCR5
ligands MIP-1  and MIP-1 . Cf2Th cells stably express-
ing comparable levels of wild-type, AATS, SSAA, and
AAAA variants of CCR5 were selected by fluorescence-
activated cell sorting, using a phycoerythrin-conjugated
2D7 antibody that recognizes a conformation-dependent
epitope in the second extracellular loop of CCR5. The
expression level of CCR5 on these cells was tested in par-
allel with each binding experiment, using the 2D7 anti-
body and the 3A9 antibody, which recognizes a linear
epitope in the CCR5 NH2 terminus (data not shown). As
shown in Fig. 4 A, [125I]MIP-1  bound to cells expressing
the SSAA mutant with a slightly higher affinity than to
cells expressing wild-type CCR5 (measured dissociation
constants of 0.91   0.8 nM and 1.6   0.9 nM for SSAA
and wild-type CCR5, respectively). More interestingly,
MIP-1  exhibited dramatically impaired binding to cells
expressing the AATS and AAAA mutants, which are not
efficiently O-glycosylated (Fig. 4 A). Almost identical
binding results were obtained using MIP-1  (Fig. 4 B).
MIP-1  also bound slightly more efficiently to the SSAA
mutant (Kd value of 2.06   0.5 nM) than to the wild-type
receptor (Kd of 7.2   0.6 nM). Binding of MIP-1  to the
AATS and AAAA mutants was significantly impaired but
was higher than the negligible binding of MIP-1  to
these variants.
The dramatically reduced interaction of MIP-1  and
MIP-1  with the glycosylation-deficient AATS mutant re-
sulted in reduced efficiency of Ca2  mobilization. As
shown in Fig. 4, C and D, the peak Ca2  influx after a
stimulation of Cf2Th cells expressing the AATS variant
with 10 nM chemokine is  3–5 times lower than that seen
in cells expressing similar levels of wild-type receptor or
the SSAA mutant.
We also examined the binding affinities of MIP-1  to
the SATS and ASTS mutants, which can be O-glycosylated
at serine 6 and 7, respectively. Cf2Th transfectants tran-
siently expressing similar surface levels of the CCR5 vari-
ants were used for binding assays. The SATS variant bound
MIP-1  with an affinity comparable to that of wild-type
CCR5, but MIP-1  association with the ASTS mutant
was significantly less efficient (relative Kd value of 19.9  
1.3 nM) (Fig. 4 E). Thus, O-glycosylation of serine 6 on
CCR5 is optimal for MIP-1  binding.
Chemokine Binding to O-glycosylation–defective CHO Cells
Expressing Human CCR5. The CHO-derived ldlD cells
lack the epimerase needed to synthesize UDP-galactose
and UDP-N-acetylgalactosamine from UDP-glucose or
UDP-N-acetylglucosamine, respectively (29). This defect
completely prevents O-glycosylation of proteins and im-
pairs maturation of N-linked carbohydrate chains (29).
This phenotype can be reversed by addition of Gal and
GalNAc to the cell culture media. To confirm that O-gly-
cosylation of CCR5 is necessary for high affinity binding
of chemokines, we generated ldlD cells stably expressing
human CCR5 with a C9 tag to perform binding experi-
ments. The 1D4 antibody directed against the C9 peptide
tag was used to precipitate CCR5 from the lysates of la-
beled ldlD-CCR5 cells cultured in Gal/GalNAc-deficient
medium. CCR5 in these cells migrated with an apparent
molecular mass 2–3 kD smaller than that of CCR5 from
cells grown in the same medium supplemented with 50
 M Gal/500  M GalNAc (Fig. 5 A). The CCR5 from
the ldlD-CCR5 cells cultured in Gal/GalNAc-supple-
mented medium migrated comparably to CCR5 expressed
in the parental CHO cells. These results are consistent
with the expected O-glycosylation of CCR5 in the ldlD-
CCR5 cells that is conditionally dependent upon the avail-
ability of Gal/GalNAc.
Competitive binding assays with MIP-1  and MIP-1 
were performed with the ldlD-CCR5 cells. Addition of
Gal/GalNAc to the medium did not significantly change
Figure 3. Contribution of O-glycosylation to HIV-1 and SIV entry.
Cf2Th cells stably expressing CD4 were transfected with plasmids encod-
ing wild-type CCR5 or the indicated mutants. 2 d after transfection, the
CCR5 expression level was assessed by FACS® analysis of a cell sample
stained with phycoerythrin-conjugated 2D7 antibody. Cells expressing
similar levels of the CCR5 variants were infected with recombinant
CAT-expressing viruses pseudotyped with different HIV-1 and SIV en-
velope glycoproteins. 3 d later, the CAT activity in cell lysates was mea-
sured. The results represent means and standard deviations of triplicate
samples. One representative experiment of four performed is shown.1667 Bannert et al.
the staining of the cells with phycoerythrin-conjugated
2D7 antibody (Fig. 5 legend), suggesting that the glycosyla-
tion state of CCR5 does not greatly affect surface expres-
sion of the protein in ldlD cells. Binding of both MIP-1 
and MIP-1  was significantly lower to ldlD-CCR5 cells
grown in Gal/GalNAc-deficient medium than to these
cells cultured in Gal/GalNAc-containing medium (Fig. 5,
B and C). No specific binding of either chemokine was de-
tected to ldlD cells lacking CCR5. These results confirm
the importance of O-glycosylation for the ability of wild-
type CCR5 to bind its chemokine ligands.
Contribution of Sialic Acid Moieties on the CCR5 O-glycan
to Chemokine Binding. A common modification of
O-linked carbohydrate chains is the addition of sialic acid
residues by sialyltransferases. The important role that nega-
tive charges in the NH2 terminus of CCR5 play with re-
spect to ligand binding prompted us to examine the effect
on chemokine binding of removing only sialic acids from
Figure 4. Effects of changes in CCR5 O-glycosylation sites on binding
and signaling of MIP-1  and MIP-1 . Cf2Th cells stably expressing CCR5
variants were incubated with 0.1 nM 125I-MIP-1  (A) or 125I-MIP-1  (B)
and increasing amounts of unlabeled competitor. Cells were washed and
bound labeled chemokine was quantitated in a  -counter. The binding data
were analyzed with Prism software (GraphPad) (reference 27). FACS®
measurements were done in parallel on the same cells using phycoerythrin-
conjugated 2D7 antibody. Mean fluorescence for cells expressing wild-type
(wt) CCR5 was 469 (100%); for SSAA, 434 (92.5%), for AATS, 375 (80%),
and for AAAA, 399 (85.1%). The experiments shown are representative of
four binding assays performed with similar results. The same cells expressing
wild-type CCR5 or the SSAA or AATS mutants, as well as CCR5-nega-
tive parental Cf2Th cells, were transfected with a plasmid encoding the G
protein subunit G 16, loaded with the indicator dye Fura-2, and used to
measure changes in intracellular Ca2  concentrations after stimulation (ar-
rowhead) with 10 nM MIP-1  (C) or 10 nM MIP-1  (D). Ca2  influx is
shown as the ratio of the fluorescence signals observed at 510 nm after exci-
tation at 340 and 380 nm. The curves were superimposed for comparison
and are representative of the results obtained in the two experiments per-
formed. (E) Homologous competition experiment with MIP-1  similar to
B except that Cf2Th cells transiently expressing CCR5 variants were used.
The mean fluorescence intensities of the cells stained with the 2D7 antibody were: wild-type, 174 (100%); AATS, 174 (100%); SATS, 139 (79.9%);
ASTS, 152 (87.4%). A representative experiment of three, all with similar results, is shown.1668 CCR5 O-Glycans and Chemokine Binding
the CCR5 O-glycan. A 1.5-h treatment of 35S-labeled
Cf2Th cells expressing wild-type CCR5 with 0.3 units of
sialidase from Arthrobacter ureafaciens, which hydrolyzes ter-
minal  2–3,  2–6, and  2–8-linked acylneuraminic acids,
led to a visible shift in migration of the immunoprecipitated
CCR5 band on SDS-PAGE (Fig. 6 A). In the presence of
0.1% sodium azide to prevent receptor internalization, sial-
idase treatment had no effect on the expression level of
CCR5, as determined by staining cells with phycoerythrin-
conjugated 2D7 antibody (data not shown). Binding of
MIP-1  and MIP-1  to sialidase-treated Cf2Th cells ex-
pressing wild-type CCR5 was almost completely abolished
(Fig. 6, B and C). As expected, no specific binding of chemo-
kines to the CCR5 NH2-terminal deletion mutant, CCR5 2–
17, could be detected (Fig. 6 B, and data not shown).
Contribution of Sulfation of NH2-terminal CCR5 Tyrosines
to Chemokine Binding. Sulfation of tyrosines 10, 14, and
15 in the CCR5 NH2 terminus has been shown to be im-
portant for HIV-1 binding and entry (21). Treatment of
CCR5-expressing cells with sodium chlorate, an inhibitor
of tyrosine sulfation, lowered the affinity of CCR5 for
MIP-1  and MIP-1  (21). To examine the contribution of
specific CCR5 NH2-terminal tyrosine sulfates to chemo-
kine binding, CCR5 mutants with alterations in one or
more of the tyrosines at positions 3, 10, 14, and 15 were
used. Cf2Th cell lines expressing comparable levels of the
mutants were established, and equivalent surface expression
of the CCR5 variants was verified by 2D7 antibody stain-
ing in parallel with the binding assays. The CCR5 mutants
are named according to the amino acid residues located at
positions 3, 10, 14, and 15. Previous studies (21) demon-
strated that alteration of all four NH2-terminal CCR5
tyrosines to phenylalanine (FFFF) or to aspartic acid
(DDDD) resulted in a loss of sulfate incorporation. Resto-
ration of individual tyrosines in the context of the DDDD
mutant resulted in mutant proteins (YDDD, DYDD,
DDYD, and DDDY) that incorporated sulfate (21). Thus,
all of the CCR5 NH2-terminal tyrosines can potentially be
sulfated, and the study of mutants (FDDD, DFDD, DDFD,
and DDDF) in which the restored tyrosines are converted
to phenylalanine allows an assessment of the contribution
of sulfation of a specific tyrosine to a phenotype. Changes
in all four NH2-terminal CCR5 tyrosines resulted in  70–
200-fold decreases in the affinity of MIP-1  and RANTES
(Table I). Restoration of tyrosine 3 in the YDDD mutant
did not restore the efficient binding of MIP-1 . Restora-
tion of tyrosines 10, 14, and 15 all resulted in improved
chemokine binding in the context of the DDDD mutant.
In the case of tyrosine 14, this improvement was signifi-
cantly better for the restoration of tyrosine than for a phe-
nylalanine substitution. This suggests that, for both MIP-
1  and RANTES, the presence of sulfation on tyrosine 14
contributes to the interaction with CCR5. By similar rea-
soning, the data in Table I suggest that the sulfation of ty-
Figure 5. Effect of O-glycosyla-
tion of CCR5 expressed in ldlD
cells on chemokine association.
The addition of O-glycans in ldlD
cells depends on the presence of
GalNAc and Gal in the culture
media. Parental CHO cells express-
ing CCR5 were grown in normal
F12 medium, as described in Mate-
rials and Methods. ldlD cells stably
expressing CCR5 were grown for
48 h in F12 medium supplemented
with 2% dialyzed FCS and ITS, ei-
ther with or without 500  M Gal-
NAc and 50  M Gal. (A) Cells
were labeled for 8 h with [35S]cys-
teine/methionine. CCR5 was pre-
cipitated with the 1D4 antibody
from cell lysates and subjected to
SDS-PAGE. Homologous compet-
itive binding assays with MIP-1 
(B) and MIP-1  (C) were per-
formed on CCR5-expressing ldlD-
CCR5 cells and, to assess nonspe-
cific binding, on CCR5-negative
ldlD cells. The mean fluorescence
values determined with phyco-
erythrin-conjugated 2D7 antibody
in parallel to the binding assays
were 3.6 for ldlD cells, 176.1
(100%) and 134 (76.1%) for ldlD-
CCR5 cells grown with or with-
out GalNAc and Gal, respectively.
Experiments are representatives of
two (B) or three (C) assays per-
formed with similar results.1669 Bannert et al.
rosine 15 contributes to the binding of RANTES but not
that of MIP-1 . Thus, chemokine binding is facilitated by
sulfation of NH2-terminal CCR5 tyrosines, particularly ty-
rosine 14 and, for RANTES, tyrosine 15.
Discussion
The interaction of chemokines and their receptors is
characterized by promiscuity and redundancy, properties
that allow these proteins to be involved in a wide variety of
immunological processes (1–3, 30). How do chemokine
receptors, whose extracellular domains are characterized by
limited protein surface, achieve specific, high-affinity inter-
actions while maintaining the flexibility to bind different
ligands? Here we show that posttranslational modification
of the CCR5 chemokine receptor by the addition of
O-linked glycans and tyrosine sulfates contributes to che-
mokine binding. These modifications provide not only a
larger and potentially more flexible binding surface, but
also supply an array of negative charges that allow electro-
static interactions with the generally positive receptor-
binding face of the chemokines.
As an initial step in evaluating the functional significance
of CCR5 glycosylation, we characterized the location and
extent of this modification. Glycan chains are commonly
added to chemokine receptors, either by N-linkage to an
asparagine residue in the sequon asparagine-X-serine/thre-
Figure 6. Effect of sialidase
treatment of Cf2Th cells express-
ing CCR5 on chemokine bind-
ing. CCR5-expressing Cf2Th
cells were divided into two groups
and incubated with either sialidase
or buffer without enzyme. (A)
Sialidase treatment increased
CCR5 mobility on a reducing
SDS-polyacrylamide gel. Cells
were labeled with 35S-cysteine/
methionine overnight before in-
cubation with buffer alone ( ) or
sialidase ( ). Subsequently, cells
were lysed and the lysates precipi-
tated with the 1D4 antibody. Ho-
mologous competitive binding as-
says with MIP-1  (B) and MIP-1 
(C) were performed on Cf2Th
cells expressing wild-type CCR5
after sialidase treatment. Cells ex-
pressing the deletion mutant
CCR5 2–17 were included in
(B) to determine nonspecific
chemokine binding. Sialidase
treatment did not change the
mean fluorescence of cells stained
with the phycoerythrin-conju-
gated 2D7 antibody (data not
shown). wt, wild-type.
Table I. Chemokine Binding to CCR5 Mutants with Changes in 
NH2-terminal Tyrosines
 Ligand CCR5 variantsa MIP-1  RANTES
Wild-type (YYYY) 0.33   0.2 0.38   0.12
FFFF 32   2.5 74   18
DDDD 22   5.4 83   22
YDDD 25   4.4 ND
FDDD 98   40 ND
DYDD 4.5   1.2 ND
DFDD ND ND
DDYD 3.0   1.2 3.6   1.8
DDFD 14   4.0 20   5.0
DDDY 2.4   0.7 8.9   1.0
DDDF 3.0   1.8 25   6.8
The Kd values (nM) and standard errors were calculated from the results
of experiments in which the CCR5 variants exhibited comparable levels
of surface expression. The data were analyzed with GraphPad Prism
software, using an algorithm for homologous one-site competition
binding with ligand depletion (reference 27). The average Kd from two
or three experiments is shown, with the highest standard error of each
experiment reported. ND, not determined.
aThe names of the CCR5 mutants reflect the identity of the amino ac-
ids at positions 3, 10, 14, and 15.1670 CCR5 O-Glycans and Chemokine Binding
onine or by O-linkage to a serine or threonine. CCR5
contains one potential N-linked glycosylation site (aspar-
agine 268 - cysteine 269 - serine 270) in the third extracel-
lular loop, but this site is not used (21, 31). Cysteine 269 in
the consensus sequence is thought to be involved in the
formation of a disulfide bond with cysteine 20 in the NH2
terminus, perhaps limiting the accessibility of this region to
glycosyltransferases. CCR5 has been shown to be O-gly-
cosylated (21) and has four serine/threonine-rich regions
in its extracellular domains. Our mutagenic analysis of
these regions indicates that the major CCR5 O-glycosyla-
tion site in all cells tested, including primary macrophages,
involves a pair of serines at positions 6 and 7. A mutant
CCR5 protein with serine to alanine changes at these po-
sitions demonstrated an  2-kD shift on SDS-PAGE and
migrated with the same mobility as enzymatically deglyco-
sylated wild-type protein. The ASTS and SATS mutants,
in which serine 6 and 7, respectively, are individually con-
verted to alanine, migrated similarly to the wild-type
CCR5 protein. This result indicates that either serine 6 or
serine 7 can be glycosylated but only one of them is modi-
fied in wild-type CCR5.
Our studies suggest that a second potential O-glycosyla-
tion site in the CCR5 NH2 terminus, at threonine 16/
serine 17, can be modified by galactose-containing glycans
under some circumstances. The AATS mutant, in which
serines 6 and 7 are converted to alanines, incorporated ga-
lactose at a reduced level compared with the wild-type
CCR5. This galactose incorporation was abolished by the
additional conversion of threonine 16 and serine 17 to ala-
nines in the AAAA mutant, indicating the dependence of
this modification on the second potential O-glycosylation
site in the CCR5 NH2 terminus. The AATS and AAAA
mutants labeled with [35S]cysteine/methionine migrated
indistinguishably on SDS-polyacrylamide gels. Further-
more, enzymatic deglycosylation of the AATS mutant does
not result in a detectable shift in its migration. These obser-
vations suggest that the sugar moiety added to either threo-
nine 16 or serine 17 in the AATS mutant is relatively small
and likely consists of a T antigen structure (Gal  1–3 Gal-
NAc  - Ser/Thr).
It is unclear whether O-glycosylation of either threonine
16 or serine 17 occurs in wild-type CCR5. The compara-
ble migration and efficiency of galactose incorporation ob-
served for wild-type CCR5 and the SSAA mutant in
which threonine 16 or serine 17 are both converted to ala-
nines, indicate that any O-glycosylation at this site involves
short glycan chains. It is also quite possible that preventing
glycosylation at the preferred site, serines 6 and 7, in the
AATS mutant promotes aberrant glycosylation at threonine
16/serine 17. A similar effect has been reported for vaso-
pressin receptor 2, where the removal of one glycosylation
site resulted in other sites becoming available to glycosyl-
transferases (32). Our most extensive studies were per-
formed in Cf2Th cells and it should be kept in mind that
utilization of the potential O-glycosylation site at threonine
16 and serine 17 could vary with cell type or the differenti-
ation or activation state of the cell (24).
Efficient O-glycosylation of CCR5 appears to be limited
to the NH2 terminus, based on the phenotypes of the
CCR5 2–17 and AAAA mutants. The serine/threonine-
rich regions in the CCR5 second and third extracellular
loops occur adjacent to cysteine residues involved in disul-
fide bonds. Like the potential N-glycosylation site, these
potential sites of O-glycosylation may not be accessible due
to close interactions of these regions with other elements of
the CCR5 ectodomain.
To date, only a few instances of O-glycosylation of
GPCRs have been documented (32) and little is known
about the presence of this modification on chemokine re-
ceptors and its potential contribution to the physiologic
function of these proteins. The results of our homologous
competition binding experiments and Ca2  mobilization
assays performed with MIP-1  and MIP-1  demonstrate
that O-glycosylation of CCR5 at serine 6 or 7 is necessary
for high affinity binding of both chemokines. Results anal-
ogous to those obtained with CCR5 mutants were ob-
served for the wild-type CCR5 expressed in ldlD cells,
which are conditionally defective for O-linked sugar addi-
tion. Most of the contribution of the O-linked glycans on
CCR5 to chemokine binding appears to depend upon the
negatively charged sialic acids. The sialic acids likely make
specific contacts with basic residues on the chemokine sur-
face thought to interact with CCR5 (33, 34). The binding
of MIP-1  was disrupted more than that of MIP-1  by
removal of the CCR5 O-glycans or sialic acid, suggesting
different degrees of contact between the negatively
charged glycans and the binding surfaces of different che-
mokine ligands.
The chemokine binding studies provide clues that serine
6 is the preferred site of O-glycosylation on wild-type
CCR5. The SATS mutant, in which serine 7 is changed to
alanine, bound chemokine with an affinity comparable to
that of wild-type CCR5. This is consistent with other mu-
tagenic studies of CCR5 in which serine 7 was altered (13).
By contrast, replacement of serine 6 with alanine (ASTS
mutant) resulted in a decreased chemokine binding affinity
of  3–4-fold, despite the O-glycosylation of this mutant at
serine 7. A similar decrease in chemokine binding has been
observed for a CCR5 mutant in which serine 6 is con-
verted to proline (33). Thus, although O-glycosylation at
serine 7 contributes somewhat to chemokine binding, the
presence of O-linked glycans on serine 6 is optimal for the
interaction of CCR5 with chemokine ligands. Because
MIP-1  binds comparably to wild-type CCR5 and the
SATS mutant, but binds less well to the ASTS mutant, the
wild-type CCR5 probably is O-glycosylated predomi-
nantly on serine 6.
Further studies will be required to define the structure
of the O-glycans added to CCR5. CHO cells do not ex-
press core 2  1,6-N-acetylglucosaminyltransferase and
 1,3-fucosyltransferase (35) and, as a result, O-linked car-
bohydrates added to proteins produced in CHO cells are
typically relatively short, core-1 O-glycans (36–43). Our
data demonstrating MIP-1  and MIP-1  binding to
CCR5 expressed in CHO or IdID cells indicate that the1671 Bannert et al.
addition of such core-1 structures is sufficient to allow the
interaction with chemokines.
It has been shown previously that glycosylation is re-
quired to maintain high-affinity SDF-1  binding (44) and
influences the ability of CXCR4 to serve as a coreceptor
for T-tropic (X4) and dual-tropic (R5X4) HIV-1 strains
(45). Removal of a site of N-linked glycosylation allows
CXCR4 to serve as a more universal coreceptor, allowing
efficient entry of several HIV-1 isolates that normally use
only CCR5 (45). We tested the impact of O-glycosylation
on the ability of CCR5 to serve as a coreceptor for HIV-1
and SIV. The absence of O-glycans on CCR5 did not sig-
nificantly influence HIV-1 and SIV entry efficiency. It is
possible that such an influence might be revealed in target
cells with lower receptor density. O-glycosylation–defi-
cient CCR5 mutants did not support the entry of viruses
pseudotyped with the T-tropic (X4) HXBc2 envelope gly-
coproteins (data not shown).
The binding of HIV-1 envelope glycoproteins to CCR5
and the entry of R5 viruses into CCR5-expressing cells is
greatly influenced by the sulfation of tyrosines 10, 14, and
15 in the CCR5 NH2 terminus (21). Treatment of CCR5-
expressing cells with sodium chlorate, an inhibitor of tyro-
sine sulfation, decreased the binding affinity of the HIV-1
gp120 envelope glycoprotein and  -chemokines (21).
Here, using a mutagenic approach, we provide evidence for
the contribution of sulfation of tyrosine 14 in the CCR5
NH2 terminus to the binding of both MIP-1  and
RANTES. Although the presence of a phenyl group in the
side chain of CCR5 residue 15 contributes to both MIP-1 
and RANTES binding, the sulfate moiety on tyrosine 15
appears to be more important for the binding of RANTES
than that of MIP-1 . Our data are also consistent with a
contribution of the tyrosine sulfate at position 10 to MIP-
1  binding, although the specific contribution of sulfate
was not addressed. Finally, as was previously seen for HIV-1
gp120 binding (21), the tyrosine sulfate at position 3 of
CCR5 makes little contribution to chemokine binding.
Together, our results demonstrate a significant role of
posttranslational modification of the CCR5 NH2 terminus
in binding the natural chemokine ligands. Sialylated
O-linked oligosaccharides and sulfated tyrosines provide an
array of negative charges on a potentially flexible substruc-
ture, allowing electrostatic interactions with the structurally
diverse, basic surfaces of different chemokines. High-affin-
ity binding must, in addition, require more specific con-
tacts between the chemokine and the CCR5 sulfotyrosines
and sialic acids; this conclusion follows from the observa-
tion that acidic amino acid residues cannot effectively sub-
stitute for these moieties. A potential  -turn involving pro-
line 8 on CCR5 may bring the O-glycans attached to
serine 6 into proximity with the tyrosine sulfate–rich
stretch at residues 10–15, facilitating such specific contacts.
The NH2 termini of several chemokine receptors are rich
not only in tyrosines that can be potentially sulfated (21),
but also in serines and threonines. This suggests that post-
translational modifications by sulfate and O-linked oli-
gosaccharides may be common among the chemokine re-
ceptors and play roles in ligand binding similar to those
demonstrated for CCR5.
Striking parallels exist between the structures implicated
in chemokine binding by CCR5 and those contributing to
selectin-mediated intercellular adhesion. Sialyl lewis X
structures on core 2 branched O-linked oligosaccharides,
together with the sulfation of closely located amino-termi-
nal tyrosines, provide the basis for specific interaction of
some type of selectin ligands with their counter-receptors.
For example, PSGL-1 (P-selectin glycoprotein ligand-1)
contains three tyrosines close to the NH2-terminal mucin-
like glycosylation site. Sulfation of one of these tyrosines
in addition to the sialyl lewis X glycan(s) is essential for
P-selectin binding (46–49). In this case, the position, struc-
ture, and chirality of the O-linked carbohydrate can influ-
ence the affinity of the interaction (49–52).
All  - and  -chemokines, including MIP-1 , MIP-1 ,
and RANTES, bind sulfated glycosaminoglycans (53, 54).
These less specific electrostatic associations may serve to
concentrate the chemokines near the target cell surface,
setting the stage for more specific interactions with the
chemokine receptor. It is possible that the properties of in-
dividual chemokines may similarly impact binding to both
glycosaminoglycans and chemokine receptors. In this con-
text, it is interesting that Ali and colleagues reported that
MIP-1 , but not MIP-1 , bound to CCR5-expressing
cells much more efficiently when glycosaminoglycans were
present on the cell surface (55). This might reflect some of
the differences that we observed in the impact of O-glyco-
sylation on MIP-1  and MIP-1  binding. Additional work
should further elucidate the molecular interactions that al-
low chemokines to exert their effects on diverse targets.
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